Login Register Cart 0
Generic placeholder image

Cardiovascular & Hematological Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5257
ISSN (Online): 1875-6182

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Clinical Trial

Sacubitril-Valsartan Improves Anemia of Cardiorenal Syndrome (CRS)

Author(s): Nicolás R. Robles *, Rosa D. Campillejo, Julian Valladares, Elena G. de Vinuesa, Juan Villa and Guillermo Gervasini

Volume 19, Issue 1, 2021

Published on: 06 May, 2020

Page: [93 - 97] Pages: 5

DOI: 10.2174/1871525718666200506095537

Price: $65

Abstract

Background and Aims: Anemia is a common complication of heart failure and Chronic Kidney Disease (CKD). Sacubitril-valsartan is a novel therapy for the treatment of chronic Heart Failure with a reduced Ejection Fraction (HFrEF). We have evaluated the short-term effects of sacubitril- valsartan on the anemia of CRS.

Methods: The study group comprised 39 patients with HFrEF, who were followed-up for three months. The study is a retrospective analysis of clinical data. Data of 3 months’ and baseline visits were recorded including plasmatic creatinine, glomerular filtration rate, cystatin C, kaliemia, haemoglobin, pro-BNP, and albuminuria.

Results: In all, 34 patients ended the follow-up. Mean sacubitril-valsartan dosage at baseline was 101 ± 62 mg/day and 126 ± 59 mg/day at end. Mean hemoglobin increased from 12.2 ± 1.1 g/dl at baseline to 12.9 ± 1.0 g/dl (p = 0.001,). Prevalence of anemia was 64.7% (95%CI, 47.9-78.5%) at baseline and 38.4 (95%CI, 23.9-55.0%) after the follow-up (p = 0.016). Serum cystatin C levels decreased from 2.71 ± 1.0 to 2.48 ± 1.0 mg/l (p = 0.028). Serum K levels remained unchanged (baseline 4.94 ± 0.60, three months visit 4.94 ± 0.61 mmol/l, p = 0.998).

Conclusion: Sacubitril-valsartan improves anemia in CRS patients. An improvement in serum cystatin levels was observed. Few untoward effects were detected. These findings should be confirmed in wider clinical trials.

Keywords: Anemia, cardio-renal syndrome, chronic kidney disease, cystatin C, heart failure, sacubitril-valsartan.

« Previous
Graphical Abstract

[1]
Ronco, C.; Haapio, M.; House, A.A.; Anavekar, N.; Bellomo, R. Cardiorenal syndrome. J. Am. Coll. Cardiol., 2008, 52(19), 1527-1539.
[http://dx.doi.org/10.1016/j.jacc.2008.07.051] [PMID: 19007588]
[2]
Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. [Available from:, https://www.who.int/vmnis/indicators/haemoglobin/en/[Accessed: 27 April 2019]
[3]
Goodnough, T.L.; Comin-Colet, J.; Leal-Noval, S. Management of anemia in patients with congestive heart failure. Am. J. Hematol., 2017, 92(1), 88-93.
[http://dx.doi.org/10.1002/ajh.24595] [PMID: 27779769]
[4]
Abebe, T.B.; Gebreyohannes, E.A.; Bhagavathula, A.S.; Tefera, Y.G.; Abegaz, T.M. Anemia in severe heart failure patients: Does it predict prognosis? BMC Cardiovasc. Disord., 2017, 17(1), 248.
[http://dx.doi.org/10.1186/s12872-017-0680-5] [PMID: 28915848]
[5]
Gervasini, G.; Robles, N.R. Potential beneficial effects of sacubitril-valsartan in renal disease: A new field for a new drug. Exp. Op. Investig. drugs,, 2017, 26(5), 651-659.
[http://dx.doi.org/10.1080/13543784.2017.1317345] [PMID: 28388237]
[6]
Smith, G.L.; Lichtman, J.H.; Bracken, M.B.; Shlipak, M.G.; Phillips, C.O.; DiCapua, P.; Krumholz, H.M. Renal impairment and outcomes in heart failure: Systematic review and meta-analysis. J. Am. Coll. Cardiol., 2006, 47(10), 1987-1996.
[http://dx.doi.org/10.1016/j.jacc.2005.11.084] [PMID: 16697315]
[7]
McClellan, W.M.; Langston, R.D.; Presley, R. Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J. Am. Soc. Nephrol., 2004, 15(7), 1912-1919.
[http://dx.doi.org/10.1097/01.ASN.0000129982.10611.4C ] [PMID: 15213281]
[8]
Kannel, W.B. Epidemiology and prevention of cardiac failure: Framingham study insights. Eur. Heart J., 1987, 8, 23-26.
[http://dx.doi.org/10.1093/eurheartj/8.suppl_F.23] [PMID: 3665963]
[9]
Herzog, C.A.; Muster, H.A.; Li, S.; Collins, A.J. 2004 Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the medicare population. J. Cardiac Failure, 10(6), 467-472.
[http://dx.doi.org/10.1016/j.cardfail.2004.03.003] [PMID: 15599836]
[10]
Christensson, A.G.; Grubb, A.O.; Nilsson, J.Å.; Norrgren, K.; Sterner, G.; Sundkvist, G. Serum cystatin c advantageous compared with serum creatinine in the detection of mild but not severe diabetic nephropathy. J. Internal Med., 2004, 256(6), 510-518.
[http://dx.doi.org/10.1111/j.1365-2796.2004.01414.x] [PMID: 15554952]
[11]
Singh, D.; Whooley, M.A.; Ix, J.H.; Ali, S.; Shlipak, M.G. Association of cystatin C and estimated GFR with inflammatory biomarkers: The heart and soul study. Nephrol. Dial. Transplant., 2007, 22(4), 1087-1092.
[http://dx.doi.org/10.1093/ndt/gfl744] [PMID: 17210589]
[12]
Taglieri, N.; Fernandez-Berges, D.J.; Koenig, W.; Consuegra-Sanchez, L.; Fernandez, J.M.C.; Robles, N.R.; Sánchez, P.L.; Beiras, A.C.; Orbe, P.M.M.; Kaski, J.C. Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis, 2010, 209(1), 300-305.
[http://dx.doi.org/10.1016/j.atherosclerosis.2009.09.022] [PMID: 19819453]
[13]
Wang, T.D.; Tan, R.S.; Lee, H.Y.; Ihm, S.H.; Rhee, M.Y.; Tomlinson, B.; Pal, P.; Yang, F.; Hirschhorn, E.; Prescott, M.F.; Hinder, M. Effects of sacubitril/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension. Hypertension, 2017, 69(1), 32-41.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.116.08484] [PMID: 27849566]
[14]
Davis, B.J.; Johnston, C.I.; Burrell, L.M.; Burns, W.C.; Kubota, E.; Cao, Z.; Cooper, M.E.; Allen, T.J. Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia, 2003, 46(7), 961-971.
[http://dx.doi.org/10.1007/s00125-003-1121-9] [PMID: 12838387]
[15]
Einhorn, L.M.; Zhan, M.; Walker, L.D.; Moen, M.F.; Seliger, S.L.; Weir, M.R.; Fink, J.C. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch. Intern. Med., 2009, 169(12), 1156-1162.
[http://dx.doi.org/10.1001/archinternmed.2009.132 ] [PMID: 19546417]
[16]
Weir, M.R.; Rolfe, M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin. J. Am. Soc. Nephrol., 2010, 5(3), 531-548.
[http://dx.doi.org/10.2215/CJN.07821109] [PMID: 20150448]
[17]
Desai, A.S.; Vardeny, O.; Claggett, B.; McMurray, J.J.; Packer, M.; Swedberg, K.; Rouleau, J.L.; Zile, M.R.; Lefkowitz, M.; Shi, V.; Solomon, S.D. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: A secondary analysis of the PARADIGM-HF trial. JAMA Cardiol., 2017, 2(1), 79-85.
[http://dx.doi.org/10.1001/jamacardio.2016.4733] [PMID: 27842179]
[18]
Onoyama, K.; Sanai, T.; Motomura, K.; Fujishima, M. Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients. J. Cardiovasc. Pharmacol., 1989, 13, 27-30.
[http://dx.doi.org/10.1097/00005344-198900133-00007 ] [PMID: 2474097]
[19]
Kwack, C.; Balakrishnan, V.S. Managing erythropoietin hyporesponsiveness. Semin. Dial., 2006, 19(2), 146-151.
[http://dx.doi.org/10.1111/j.1525-139X.2006.00141.x ] [PMID: 16551293]
[20]
Robles, N.R.; Angulo, E.; Grois, J.; Barquero, A. Comparative effects of fosinopril and irbesartan on hematopoiesis in essential hypertensives. Ren. Fail., 2004, 26(4), 399-404.
[http://dx.doi.org/10.1081/JDI-120039824] [PMID: 15462108]

Rights & Permissions Print Cite
Article Metrics
57
1
© 2024 Bentham Science Publishers | Privacy Policy